uploads/2018/04/dna-1811955_1920-1.jpg

How Analysts View BioMarin Pharmaceuticals and Peers in April

By

Updated

Company overview

BioMarin Pharmaceuticals (BMRN) is a global biotechnology company focused on the development and commercialization of innovative therapies for serious and life-threatening rare diseases and medical conditions. It targets product candidates that offer a first-to-market opportunity or a significant benefit over existing products.

BioMarin’s product portfolio consists of six commercial-stage products and multiple clinical and pre-clinical product candidates.

Article continues below advertisement

Analysts’ recommendations

Of the 23 analysts covering BioMarin Pharmaceuticals in April, eight analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and four analysts gave it a “hold” rating. The mean rating for the stock is ~1.8 with a target price of $114.30.

Peer ratings

Eleven of the 22 analysts covering Pfizer (PFE) in April gave the stock a “buy” or a higher rating. Nine analysts gave Pfizer a “hold” rating, and two analysts gave it a “strong sell” rating. The mean rating for the stock is ~2.6 with a target price of $40.11.

Of the 12 analysts covering Achaogen (AKAO) in April, five analysts gave the stock a “strong buy” rating, six analysts gave it a “buy” rating, and one analyst gave it a “sell” rating. The mean rating for the stock is ~1.8 with a target price of $21.56.

Of the eight analysts covering CymaBay Therapeutics (CBAY) in April, two analysts gave the stock a “strong buy” rating, and six analysts gave it a “buy” rating. The mean rating for the stock is ~1.8 with a target price of $21.50.

In the next part of this series, we’ll take a look at the therapy portfolio of BioMarin Pharmaceuticals.

Advertisement

More From Market Realist